Sanders, Donald B.Wolfe, Gil I.Benatar, MichaelEvoli, AmeliaGilhus, Nils E.Illa, IsabelKuntz, NancyMassey, Janice M.Melms, ArthurMurai, HiroyukiNicolle, MichaelPalace, JacquelineRichman, David P.Verschuuren, JanNarayanaswami, Pushpa2016-10-112016Sanders, D. B., G. I. Wolfe, M. Benatar, A. Evoli, N. E. Gilhus, I. Illa, N. Kuntz, et al. 2016. “International consensus guidance for management of myasthenia gravis: Executive summary.” Neurology 87 (4): 419-425. doi:10.1212/WNL.0000000000002790. http://dx.doi.org/10.1212/WNL.0000000000002790.0028-3878http://nrs.harvard.edu/urn-3:HUL.InstRepos:29002396Objective: To develop formal consensus-based guidance for the management of myasthenia gravis (MG). Methods: In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input. Results: Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy. Conclusion: This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.en-USJournal Article2016-10-1110.1212/WNL.0000000000002790